Aardvark Therapeutics (AARD) Competitors $12.67 +0.50 (+4.11%) As of 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock AARD vs. SYRE, PRAX, UPB, VALN, CRMD, TNGX, URGN, IMNM, ABUS, and IMTXShould you be buying Aardvark Therapeutics stock or one of its competitors? The main competitors of Aardvark Therapeutics include Spyre Therapeutics (SYRE), Praxis Precision Medicines (PRAX), Upstream Bio (UPB), Valneva (VALN), CorMedix (CRMD), Tango Therapeutics (TNGX), Urogen Pharma (URGN), Immunome (IMNM), Arbutus Biopharma (ABUS), and Immatics (IMTX). These companies are all part of the "pharmaceutical products" industry. Aardvark Therapeutics vs. Its Competitors Spyre Therapeutics Praxis Precision Medicines Upstream Bio Valneva CorMedix Tango Therapeutics Urogen Pharma Immunome Arbutus Biopharma Immatics Spyre Therapeutics (NASDAQ:SYRE) and Aardvark Therapeutics (NASDAQ:AARD) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, profitability, valuation, institutional ownership, risk, dividends, earnings and analyst recommendations. Which has stronger earnings & valuation, SYRE or AARD? Aardvark Therapeutics has lower revenue, but higher earnings than Spyre Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSpyre Therapeutics$890K1,059.38-$208.02M-$3.40-4.59Aardvark TherapeuticsN/AN/A-$20.59MN/AN/A Do analysts prefer SYRE or AARD? Spyre Therapeutics currently has a consensus price target of $56.17, indicating a potential upside of 259.81%. Aardvark Therapeutics has a consensus price target of $32.60, indicating a potential upside of 157.30%. Given Spyre Therapeutics' stronger consensus rating and higher possible upside, equities analysts plainly believe Spyre Therapeutics is more favorable than Aardvark Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Spyre Therapeutics 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 2 Strong Buy rating(s) 3.25Aardvark Therapeutics 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do institutionals and insiders believe in SYRE or AARD? 80.4% of Spyre Therapeutics shares are held by institutional investors. 15.4% of Spyre Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Does the media prefer SYRE or AARD? In the previous week, Aardvark Therapeutics had 4 more articles in the media than Spyre Therapeutics. MarketBeat recorded 9 mentions for Aardvark Therapeutics and 5 mentions for Spyre Therapeutics. Spyre Therapeutics' average media sentiment score of 0.61 beat Aardvark Therapeutics' score of 0.60 indicating that Spyre Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Spyre Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Aardvark Therapeutics 2 Very Positive mention(s) 3 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is SYRE or AARD more profitable? Aardvark Therapeutics' return on equity of 0.00% beat Spyre Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Spyre TherapeuticsN/A -71.30% -38.69% Aardvark Therapeutics N/A N/A N/A SummarySpyre Therapeutics beats Aardvark Therapeutics on 8 of the 12 factors compared between the two stocks. Get Aardvark Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for AARD and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding AARD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AARD vs. The Competition Export to ExcelMetricAardvark TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$264.05M$3.13B$5.75B$10.39BDividend YieldN/A2.39%5.75%4.64%P/E RatioN/A20.6375.7726.11Price / SalesN/A442.69544.74124.93Price / CashN/A44.6737.5461.24Price / BookN/A9.6212.876.30Net Income-$20.59M-$52.73M$3.29B$271.03M7 Day Performance12.22%0.64%-0.26%-0.15%1 Month Performance40.15%6.31%3.84%6.41%1 Year PerformanceN/A18.97%68.35%28.81% Aardvark Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AARDAardvark Therapeutics3.2335 of 5 stars$12.67+4.1%$32.60+157.3%N/A$264.05MN/A0.0018Analyst ForecastSYRESpyre Therapeutics2.5306 of 5 stars$14.88-2.9%$56.17+277.5%-39.6%$898.77MN/A-4.3873PRAXPraxis Precision Medicines2.1011 of 5 stars$42.22-6.7%$85.56+102.6%-17.1%$888.73M$7.77M-3.44110Positive NewsUPBUpstream Bio1.6051 of 5 stars$16.38-5.2%$56.50+244.9%N/A$883.05M$2.37M0.0038Positive NewsHigh Trading VolumeVALNValneva2.6023 of 5 stars$10.18+2.3%$15.00+47.3%+72.2%$874.77M$183.52M-10.39700Gap DownCRMDCorMedix3.8274 of 5 stars$11.20-4.2%$18.00+60.7%+49.7%$874.27M$43.47M14.9330Analyst RevisionHigh Trading VolumeTNGXTango Therapeutics2.0907 of 5 stars$7.60-3.4%$10.50+38.2%+4.7%$845.58M$42.07M-5.7190Positive NewsGap DownHigh Trading VolumeURGNUrogen Pharma4.1907 of 5 stars$17.95-4.9%$32.00+78.3%+37.7%$830.37M$90.40M-5.41200Positive NewsIMNMImmunome2.1321 of 5 stars$9.39-4.7%$22.89+143.8%-23.3%$817.35M$12.59M-3.0540Analyst ForecastGap DownHigh Trading VolumeABUSArbutus Biopharma2.1208 of 5 stars$4.25-3.8%$5.00+17.6%+11.7%$814.72M$15.42M-14.6690High Trading VolumeIMTXImmatics2.8241 of 5 stars$6.70+1.4%$15.00+123.9%-37.2%$814.39M$130.13M-10.31260 Related Companies and Tools Related Companies SYRE Alternatives PRAX Alternatives UPB Alternatives VALN Alternatives CRMD Alternatives TNGX Alternatives URGN Alternatives IMNM Alternatives ABUS Alternatives IMTX Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:AARD) was last updated on 9/25/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredA New Way to Double Your Retirement Income?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boo...Investors Alley | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredWarren Buffett’s #1 AI Stock: Not Mag 7, And NOT on the NasdaqNew Amazon Crisis Could Tank U.S. Stock Market A new panic is halting AI projects at Amazon and could split...Altimetry | SponsoredCrypto Gets Official Government Backing—Here's the WinnerTrump Just Signed the GENIUS Act—One Coin is About to Explode We're at the BEGINNING of smart money really ...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aardvark Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aardvark Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free AARD Stock Alerts